Samchundang Pharmaceutical is set to commercialize its Eylea biosimilar, SCD411, this year. With its overseas partners projecting sales of over 17 trillion KRW ($12.7 billion), the industry is watching closely to see if the product will successfully establish itself in the market. The company aims to leverage price competitiveness to secure market share. According to Samchundang Pharmaceutical o..

Dr. Soon-Jae Park is regarded as a research and development expert with extensive experience in drug development, clinical trials, technology exports, contract manufacturing (CMO), and business strategy. He is also recognized as an exceptional entrepreneur. Dr. Park majored in biochemistry at Yonsei University and pursued his Ph.D. at Purdue University in the United States. He later worked as a ..

Samsung Biologics announced on January 22 that it recorded KRW 4.55 trillion in revenue and KRW 1.32 trillion in operating profit on a consolidated basis last year. Revenue increased by 23%, and operating profit grew by 19% compared to the previous year. The company attributed the strong performance to increased sales from its fourth plant, full-capacity operation of its first to third plants, a..